Eupraxia Pharmaceuticals (NASDAQ:EPRX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a sell rating to a strong sell rating in a research report report published on Sunday,Wall Street Zen reports.

EPRX has been the topic of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th. Stifel Nicolaus set a $25.00 target price on Eupraxia Pharmaceuticals in a report on Thursday, September 24th. Wedbush assumed coverage on Eupraxia Pharmaceuticals in a report on Thursday, September 24th. They set an “outperform” rating and a $17.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st. Finally, Oppenheimer reiterated an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $17.17.

Eupraxia Pharmaceuticals Trading Up 2.8%

NASDAQ EPRX opened at $7.63 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The company’s 50-day simple moving average is $7.58 and its two-hundred day simple moving average is $7.25. Eupraxia Pharmaceuticals has a one year low of $5.63 and a one year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.03. Analysts forecast that Eupraxia Pharmaceuticals will post -0.90 earnings per share for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

A number of institutional investors have recently modified their holdings of EPRX. Affinity Asset Advisors LLC grew its position in shares of Eupraxia Pharmaceuticals by 429.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after buying an additional 1,289,005 shares during the last quarter. Jupiter Topco LLC purchased a new stake in Eupraxia Pharmaceuticals during the second quarter valued at approximately $6,851,000. Seven Fleet Capital Management LP purchased a new stake in Eupraxia Pharmaceuticals during the first quarter valued at approximately $5,137,000. Redmile Group LLC purchased a new stake in Eupraxia Pharmaceuticals during the first quarter valued at approximately $5,068,000. Finally, Rubric Capital Management LP acquired a new stake in Eupraxia Pharmaceuticals in the first quarter valued at approximately $5,004,000.

More Eupraxia Pharmaceuticals News

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: Eupraxia reported a third-quarter 2026 loss of $0.23 per share, narrower than the $0.26 loss analysts expected. The earnings beat may be encouraging, although the company remains loss-making. Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
• Positive Sentiment: RBC Capital initiated coverage with an Outperform rating and a $14 price target, while flagging the stock as speculative risk. The rating signals analyst optimism, balanced by the high-risk designation. RBC Capital Starts Eupraxia Pharmaceuticals at Outperform
• Negative Sentiment: The company established a $125 million at-the-market offering program, allowing it to sell shares over time. The financing provides access to capital but could dilute existing shareholders if shares are issued. Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability. Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.